Mirati Therapeutics Inc
Închisă
SectorSănătate
0
Rezumat
Modificarea prețului
24h
Minim
Maxim
Recomandări | Neutru |
|---|---|
Prognoză pe 12 luni | -0.05% downside |
Sentimentul știrilor
By Acuity
50%
50%
166 / 347 Clasament în Healthcare
Mirati Therapeutics Inc Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Știri relevante
Comparație
Modificare preț
Mirati Therapeutics Inc Așteptări
Obiectiv de preț
By TipRanks
-0.05% jos
Prognoză pe 12 luni
Medie 58.67 USD -0.05%
Maxim 59 USD
Minim 58 USD
În baza a 5 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruMirati Therapeutics Inc - Dist în ultimele 3 luni.
Sentiment
By Acuity
166 / 347 Clasament în Sănătate
Sentimentul știrilor
Neutral
Volatilitate
Sub medie
Volumul știrilor (RCV)
Sub medie
Date financiare
Cheltuieli de vânzare și administrare
Cheltuieli de exploatare
Profit pre-impozitare
Vânzări
Costul vânzărilor
Profit brut din vânzări
EBITDA
Profit operațional
$
Despre Mirati Therapeutics Inc
Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.
